{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T21:17:29Z","timestamp":1770931049633,"version":"3.50.1"},"reference-count":72,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2001,1]]},"DOI":"10.1517\/14656566.2.1.85","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T20:25:33Z","timestamp":1115238333000},"page":"85-93","source":"Crossref","is-referenced-by-count":10,"title":["Current use of biologicals for the treatment of spondyloarthropathies"],"prefix":"10.1517","volume":"2","author":[{"given":"Filip De","family":"Keyser","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, B-9000 Gent, Belgium. filip.dekeyser@rug.ac.be"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman","family":"Mielants","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, B-9000 Gent, Belgium. filip.dekeyser@rug.ac.be"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M","family":"Veys","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, B-9000 Gent, Belgium. filip.dekeyser@rug.ac.be"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2005,2,24]]},"reference":[{"key":"e_1_2_1_5_1","doi-asserted-by":"crossref","unstructured":"MIELANTS H VEYS EM: The bowel and spondylarthritis: a clinical approach. In: Spondylarthritides. Calin A Taurog J (Eds.) Oxford University Press Oxford UK (1998) :129\u2013157.","DOI":"10.1093\/oso\/9780192627490.003.0009"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70042-9"},{"key":"e_1_2_1_7_1","unstructured":"\u2022\u2022Review of the existing data on the relation between gutinflammation and spondyloarthropathy."},{"key":"e_1_2_1_8_1","first-page":"2266","volume":"22","author":"MIELANTS H","year":"1995","unstructured":"MIELANTS H, VEYS EM, DE VOS M et al.: The evolution ofthe spondyloarthropathies in relation to gut histology. I. Clinical aspects. J. Rheumatol. (1995) 22:2266\u20132272.","journal-title":"DE VOS M et al.: The evolution ofthe spondyloarthropathies in relation to gut histology. I. Clinical aspects. J. Rheumatol."},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8964393"},{"key":"e_1_2_1_10_1","first-page":"85","article-title":"Criteres declassification des spondyloarthropathies","volume":"57","author":"AMOR B","year":"1990","unstructured":"AMOR B, DOUGADOS M, MIJIYAWA M: Criteres declassification des spondyloarthropathies. Rev. Rhum. (1990) 57:85\u201389.","journal-title":"Rev. Rhum."},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380507"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780391209"},{"key":"e_1_2_1_13_1","doi-asserted-by":"crossref","unstructured":"CLEGG DO REDA DJ MEJIAS E et al.: Comparison ofsulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Verterans Affairs Co-operative Study. Arthritis Rheum. (1 9 9 6) 39:2013-2020.","DOI":"10.1002\/art.1780391210"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780391211"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.6.428"},{"key":"e_1_2_1_16_1","unstructured":"\u2022\u2022Pilot trial of infliximab in patients with spondyloarthropathy."},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E"},{"key":"e_1_2_1_18_1","unstructured":"\u2022\u2022Pilot trial of infliximab in patients with ankylosingspondylitis."},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"e_1_2_1_20_1","unstructured":"\u2022\u2022Key publication on the effects of etanercept in psoriasis andpsoriatic arthritis."},{"key":"e_1_2_1_21_1","unstructured":"BEUTLER BA: The role of TNF in health and disease. J. Rheumatol (1999) 2 6 (Suppl. 57) :16\u201321."},{"key":"e_1_2_1_22_1","unstructured":"\u2022Overview of the physiological and pathological effects of TNF-a."},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(93)90106-L"},{"key":"e_1_2_1_24_1","doi-asserted-by":"crossref","unstructured":"TARGAN SR HANAUER SB VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl. JMed. (1997) 337:1029\u20131035.","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_1_25_1","unstructured":"\u2022\u2022Key publication on the effects of infliximab in Crohn'sdisease."},{"key":"e_1_2_1_26_1","unstructured":"PRESENT D MAYER L VAN DEVENTER SJH et al.: Anti-TNF-alpha chimeric antibody (cA2) is effective in the treatment of the fistulae of Crohn's disease: a multicenter randomized double-blind placebo-controlled study. Am. J. Gastroenterol. (1997) 92:1746."},{"key":"e_1_2_1_27_1","unstructured":"\u2022\u2022Key publication on the effects of infliximab in Crohn'sdisease."},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780361206"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90628-9"},{"key":"e_1_2_1_30_1","unstructured":"\u2022\u2022Key publication on the effects of infliximab in rheumatoidarthritis."},{"key":"e_1_2_1_31_1","doi-asserted-by":"crossref","unstructured":"MAINI RN BREEDVELD FC KALDEN JR etal.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1 99 8) 41:1552-1563.","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W"},{"key":"e_1_2_1_32_1","unstructured":"\u2022\u2022Key publication on the effects of infliximab in combinationwith methotrexate in rheumatoid arthritis."},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05246-0"},{"key":"e_1_2_1_34_1","unstructured":"\u2022\u2022Key publication on the effects of infliximab in combinationwith methotrexate in rheumatoid arthritis."},{"key":"e_1_2_1_35_1","unstructured":"SCHAIBLE TF MAINI R LIPSKY PE VAN DER HEIJDE D MARSTERS PA HARRIMAN G: Long-term safety of infliximab and prevention of joint damage in patients with rheumatoid arthritis: Results of the attract trial. Gastroenterology (2000) 118 (Suppl.) :6226. 22.MORELAND LW BAUMGARTNER SW SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-7c fusion protein. N Engl. J. Med. (1997) 337:141\u2013147."},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00004"},{"key":"e_1_2_1_37_1","unstructured":"\u2022Key publication on the effects of etanercept in rheumatoid arthritis."},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400401"},{"key":"e_1_2_1_39_1","unstructured":"\u2022\u2022Key publication on the effects of etanercept in combinationwith methotrexate in rheumatoid arthritis."},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380407"},{"key":"e_1_2_1_41_1","unstructured":"\u2022Demonstration of the in situ expression of TNF-a in the sacroiliac joints in patients with ankylosing spondylitis."},{"key":"e_1_2_1_42_1","unstructured":"VAN DEN BOSCH F KRUITHOF E DE VOS M DE KEYSER F MIELANTS H: Crohn&apos;s disease associated with spondyloarthropathy: effect of TNF-OC blockade (infliximab) on the articular symptoms. Lancet (letter) (In Press)."},{"key":"e_1_2_1_43_1","unstructured":"\u2022Pilot evidence for the effect of infliximab on the locomotor manifestations of patients with Crohn's disease."},{"key":"e_1_2_1_44_1","unstructured":"ANTONI C DECHANT C OGILVIE A KALDEN-NEMETH D KALDEN JR MANGER B: Successful treatment of psoriatic arthritis with infliximab in a MItI controlled study. J. Rheumatol. (2000) 27 (Suppl. 59):24."},{"key":"e_1_2_1_45_1","unstructured":"BAETEN D VAN DAMME N VAN DEN BOSCH F et al.: Anti-TNF-a restores the T cell cytokine balance in sp on dylo ar thr op athy. Arthritis Rheum. (2000) 43 (Suppl. 9):S395."},{"key":"e_1_2_1_46_1","unstructured":"BAETEN D KRUITHOF E VAN DEN BOSCH F et al: Immunomodulatory effects of anti-TNF-a therapy on synovium in spondyloarthropathy. Arthritis Rheum. (In Press)."},{"key":"e_1_2_1_47_1","unstructured":"\u2022Demonstration of the biological effects of infliximab at the site of the synovial membrane in patients with spondyloarthropathy."},{"key":"e_1_2_1_48_1","unstructured":"VAN DAMME N DE VOS M BAETEN D et al.: T cell cytokines in gut mucosa of patients with spondyloar-thropathy reflect immune alterations in Crohn's disease. Arthritis Rheum. (1999) 42:S372. Abstract."},{"key":"e_1_2_1_49_1","unstructured":"SIEGERT S YIN Z RADBRUCH A SIEPER J BRAUN J: Evidence for a different cytokine secretion pattern of peripheral blood mononuclear cells of EILA B27+ patients with ankylosing spondylitis and HLA B27+ healthy controls compared to DIA B27-negative controls. Arthritis Rheum. (1998) 41:S287. Abstract."},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.4.263"},{"key":"e_1_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.11.1058"},{"key":"e_1_2_1_52_1","unstructured":"RITCHLIN C HAAS-SMITH S LOONEY J: Production tissue distribution and function of IL-10in psoriatic synovium. Arthritis Rheum. (1999) 42:S163. Abstract."},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401010"},{"key":"e_1_2_1_54_1","first-page":"1659","article-title":"IL-10 plasmalevels correlate with disease activity in spondyloar-thropathy","volume":"24","author":"CLAUDEPIERRE P","year":"1997","unstructured":"CLAUDEPIERRE P, RYMER JC, CHEVALIER X: IL-10 plasmalevels correlate with disease activity in spondyloar-thropathy. j Rheumatol. (1997) 24:1659\u20131661.","journal-title":"j Rheumatol"},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/00124743-200008000-00011"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0307-742X(21)00590-7"},{"key":"e_1_2_1_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(62)90223-1"},{"key":"e_1_2_1_58_1","first-page":"47","article-title":"Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation","volume":"48","author":"DE KEYSER F","year":"1999","unstructured":"DE KEYSER F, VAN DAMME N, DE VOS M, MIELANTS H, VEYS EM: Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation. Inflamm. Res. (1999) 48:47\u201354.","journal-title":"Inflamm. Res."},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)80068-P"},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365529850171710"},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v113.pm9247454"},{"key":"e_1_2_1_62_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5483.1352"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1997.4462"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02213121"},{"key":"e_1_2_1_65_1","first-page":"3530","article-title":"CHIANGMY: Inhibition of endothelial cell-leukocyte adhesion molecule expression with antisense oligonucleotides","volume":"152","author":"BENNETT CF","year":"1994","unstructured":"BENNETT CF, CONDON T, GRIMM S, CHAN H, CHIANGMY: Inhibition of endothelial cell-leukocyte adhesion molecule expression with antisense oligonucleotides. Immunol. (1994) 152:3530\u20133540.","journal-title":"Immunol."},{"key":"e_1_2_1_66_1","doi-asserted-by":"crossref","unstructured":"YACYSHYN BR BOWEN-YACYSHYN MB JEWELL L et al.:A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology (1998) 1 1 4:1133\u20131142.","DOI":"10.1016\/S0016-5085(98)70418-4"},{"key":"e_1_2_1_67_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.153.2.517"},{"key":"e_1_2_1_68_1","first-page":"1932","article-title":"DEN BOSCH F et al: Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis","volume":"25","author":"ELEWAUT D","year":"1998","unstructured":"ELEWAUT D, DE KEYSER F, VAN DEN BOSCH F et al: Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J. Rheumatol. (1998) 25:1932\u20131937.","journal-title":"J. Rheumatol."},{"key":"e_1_2_1_69_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116575"},{"key":"e_1_2_1_70_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v111.pm8898653"},{"key":"e_1_2_1_71_1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2249.1997.484-ce1378.x","article-title":"EDEN W: Experimental immunization with anti-rheumatic bacterial extract 0M-89 induces T cell responses to heat shock protein (hsp) 60 and hsp70; modulation of peripheral immunological tolerance as its possible mode of action in the treatment of rheumatoid arthritis","volume":"110","author":"BLOEMENDAL A","year":"1997","unstructured":"BLOEMENDAL A, VAN DER ZEE R, RUTTEN V, VAN KOOTEN P, FARINE J, VAN EDEN W: Experimental immunization with anti-rheumatic bacterial extract 0M-89 induces T cell responses to heat shock protein (hsp) 60 and hsp70; modulation of peripheral immunological tolerance as its possible mode of action in the treatment of rheumatoid arthritis. Clin. Exp. Immunol. (1997) 110:72\u201378.","journal-title":"Clin. Exp. Immunol."},{"key":"e_1_2_1_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/32.8.746"},{"key":"e_1_2_1_73_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009749009097631"},{"key":"e_1_2_1_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00270248"},{"key":"e_1_2_1_75_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.47.7.582"},{"key":"e_1_2_1_76_1","unstructured":"MIELANTS H VAN DEN BOSCH F GOEMAERE S et al: Theeffect of Subreum (0M8980) on the peripheral manifestations in spondyloarthropathy patients. J Rheumatol. (2000) 27 (Suppl. 59):57\u201358."}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.2.1.85","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T20:39:17Z","timestamp":1770928757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.2.1.85"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1517\/14656566.2.1.85"],"URL":"https:\/\/doi.org\/10.1517\/14656566.2.1.85","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}